Background: Breast implant associated anaplastic large cell lymphoma (BIA-ALCL) is a T-cell non-Hodgkin's lymphoma and an uncommon risk of textured breast implants. Over the past decade, concern about BIA-ALCL has been increasing among both patients and surgeons. Patients are seeking a better understanding of their BIA-ALCL risk toward identifying a personalized care plan. This quality improvement project examines the value added by pairing group-based patient education seminars with one-on-one consults.
Methods: Individual consults were held following educational group seminars. Consult field notes underwent qualitative thematic analysis. Themes were cross referenced against a quantitative chart review of patient BIA-ALCL prophylaxis decisions over time.
Results: Four key themes were identified: weighing, perceiving, guiding, and supporting. considers the risk-benefit assessments patients make when weighing their BIA-ALCL risk. describes the underlying psychosocial factors that frame patient perceptions of BIA-ALCL risk. presents the levels of guidance that patients require when making BIA-ALCL prophylaxis decisions. explores the therapeutic value of the individual consult. Ultimately, 41% of post-seminar consult attendees sought explantation, compared with 4% among patients who did not participate in this program ( < 0.001).
Conclusions: Key lessons include the following: (1) patients weigh BIA-ALCL risk against perceived surgical risks and the value of their reconstruction; (2) patients can benefit from a personalized balance of autonomy and surgeon guidance when selecting a BIA-ALCL prevention plan; (3) surgeons should seek to understand the psychosocial factors that may underlie patient perceptions of BIA-ALCL risk; and (4) individual consults can be therapeutic and help strengthen the patient-surgeon relationship.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604015 | PMC |
http://dx.doi.org/10.1097/GOX.0000000000003843 | DOI Listing |
Aesthetic Plast Surg
January 2025
Directorate General of Medical Devices and Pharmaceutical service of the Italian Ministry of Health, Via Ribotta 5, 00144, Rome, Italy.
Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.
View Article and Find Full Text PDFAesthetic Plast Surg
December 2024
Department of Neuroscience, Mental Health and Sense Organs (NESMOS), Chair of Plastic Surgery, Azienda Ospedaliera Sant'Andrea, UOD of Plastic Surgery, Sapienza University of Rome, Faculty of Medicine and Psychology, Via di Grottarossa 1035-1039, 00189, Rome, Italy.
Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.
View Article and Find Full Text PDFJ Plast Reconstr Aesthet Surg
December 2024
Carol Davila University of Medicine and Pharmacy; Department of Plastic and Reconstructive Surgery, Prof. Dr. "Agrippa Ionescu" Clinical Emergency Hospital, Bucharest, Romania.
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an uncommon malignancy, was linked to textured breast implants by moderate evidence in 2021. Documenting Romanian cases provides valuable insights into the epidemiology, management, and outcomes, thereby, enhancing global understanding and informing clinical practices. Our objective was to analyze BIA-ALCL cases in Romania, focusing on patient demographics, implant characteristics, clinical presentation, diagnostic methods, treatment, and outcomes.
View Article and Find Full Text PDFAesthetic Plast Surg
October 2024
Directorate General of Medical Devices and Pharmaceutical service, Italian Ministry of Health, Via Ribotta 5, 00144, Rome, Italy.
Background: Accurate estimation of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) incidence is crucial for assessing breast-implant-associated risk. However, the size of the implanted population worldwide is unknown, making it challenging to appropriately estimate this figure. This study aims to provide a new reliable and reproducible method to estimate the breast-implanted-population (BIP), reporting a reliable annual BIA-ALCL incidence estimate.
View Article and Find Full Text PDFPlast Reconstr Surg Glob Open
September 2024
From the Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
When a delayed seroma with a low volume is detected more than 1 year after silicone breast implant insertion, aspiration is necessary. However, if the seroma is small and difficult to collect, we may avoid puncturing it, considering the risk of damaging the implant, and the patient may be followed up intensively. Moreover, a delayed seroma is a major symptom of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!